Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

Specimen Handling 483pembrolizumab 456Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 315Biopsy 274Cisplatin 270Radiotherapy 244Paclitaxel 229Gemcitabine 225Bevacizumab 214Nivolumab 189fludarabine 184venetoclax 174Drug Therapy 171Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 145Docetaxel 144Radiosurgery 137Standard of Care 136Rituximab 125Pemetrexed 117durvalumab 114atezolizumab 110Leucovorin 110Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Janus Kinase Inhibitors × 1 year × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06715982 2025-10-28

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Hangzhou Cancer Hospital

Phase 2 Recruiting
35 enrolled

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡